You are here: Industry Insights > Bayer

News List

Bayer backs new mobile eye unit in Hampshire pharmatimes
September 26, 2017
Bayer is supporting a new mobile eye service in the UK that will offer patients in Hampshire more convenient access to treatment for age-related macular degeneration (AMD).
NICE recommends Bayer's Eylea for myopic chorodial neovascularisation pharmafile
September 25, 2017
Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea in the treatment of visual impairment due to myopic chorodial neovascularisation
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents worldpharmanews
September 22, 2017
With approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects.
Bayer’s rare cancer drug Aliqopa bags speedy approval pharmatimes
September 19, 2017
US regulators have issued an accelerated approval for Bayer’s relapsed follicular lymphoma therapy Aliqopa.
Bayer lymphoma treatment speeds to FDA approval pharmafile
September 19, 2017
The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came to the judgement that the drug should be brought to patients with relapsed follicular lymphoma.
Bayer's Nexavar approved for primary liver cancer by NICE pharmatimes
August 11, 2017
Nexavar, funded through the Cancer Drugs Fund, has been the only option of advanced liver cancer patients in England.
Bayer's liver cancer drug availability spreads to UK with NICE approval pharmafile
August 11, 2017
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) ...
Bayer receives EU approval for Regorafenib europeanpharmaceuticalreview
August 09, 2017
Bayer have announced the European Commission has granted marketing authorisation for Stivarga…
EU approved Bayer's Stivarga for the Second-Line Systemic Treatment of Liver Cancer firstwordpharma
August 08, 2017
The approval for the first treatment advance in nearly 10 years is based on data from the Phase III RESORCE research.
Bayer secures one-two treatment for liver cancer after EU approval pharmafile
August 08, 2017
Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver cancer, as second-line treatment.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page